Lundbeckfonden Ventures
VC Fund
Copenhagen, Denmark
Lundbeckfonden Ventures is a VC fund in Copenhagen focused on Biotechnology and Health Care. Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, LundbeckfondVentures invests up to € 50 million.Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.
- Total investments:
- 70
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Lundbeckfonden Ventures invests in
Stages Lundbeckfonden Ventures invests in
Countries Lundbeckfonden Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Series A
- $10M–$50M
- Series B
- $20M–$95M
- Series C
- $16M–$53M
Investment Focus
Industry
- Biotechnology 31 (44%)
- Health Care 20 (29%)
- Therapeutics 16 (23%)
- Medical 11 (16%)
- Pharmaceutical 10 (14%)
Stage
- Series B 15 (21%)
- Series A 13 (19%)
- Series C 11 (16%)
- Funding Round 7 (10%)
- Venture - Series Unknown 3 (4%)
Country
- United States 18 (26%)
- Denmark 5 (7%)
- United Kingdom 5 (7%)
- France 3 (4%)
- Spain 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jette Bundgard
Associate
|
Associate | Total investments: 0 | Find email | |
Johan Kördel
Senior Partner
|
Senior Partner | Total investments: 17 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Women in Life Science Denmark
|
WiLD is a networking platform for women in senior positions in business and academia that is motivating and focused on science. | $73.4K / Grant / Oct 28, 2025 | |
Kvantify
|
Kvantify provides Quantum computing management software developing solutions that address computational challenges. It allows and helps clients to find solutions for all sorts of challenges in life sciences, financial services, logistics, and many other functional areas to deliver value to the business.The company was founded in 2022 and isheadquartered in Copenhagen, Denmark. | $5.8M / Venture - Series Unknown / Sep 01, 2025 | |
SNIPR Biome
|
SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases. The company uses CRISPR technology that can subvert elements of the endogenous bacterial CRISPR machinery to eliminate hazardous bacteria in vivo, providing the health professionals with medicines that selectively target andkill bacteria with specific DNA sequences. | $40.9M / Series B / Aug 07, 2025 | |
ENTEROME
|
Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $19M / Venture - Series Unknown / Jun 12, 2025 | |
|
Kvantify
|
Kvantify provides Quantum computing management software developing solutions that address computational challenges. It allows and helps clients to find solutions for all sorts of challenges in life sciences, financial services, logistics, and many other functional areas to deliver value to the business.The company was founded in 2022 and isheadquartered in Copenhagen, Denmark. | $10.8M / Seed / Jul 03, 2024 | |
Notify Therapeutics
|
Notify Therapeutics develops therapies for the treatment of infertility. By targeting the early and hormone-independent phase of egg maturation, the company aims at developing a first-in-class treatment for infertile women, who do not benefit from standard hormone therapy. It utilizes drug-inducing factors that regulate the intracellular AKTpathway and target the early and hormone-independent phase of egg maturation for the treatment. | $5.3M / Sep 25, 2023 | |
|
Notify Therapeutics
|
Notify Therapeutics develops therapies for the treatment of infertility. By targeting the early and hormone-independent phase of egg maturation, the company aims at developing a first-in-class treatment for infertile women, who do not benefit from standard hormone therapy. It utilizes drug-inducing factors that regulate the intracellular AKTpathway and target the early and hormone-independent phase of egg maturation for the treatment. | $5.3M / Sep 25, 2023 | |
|
Women in Life Science Denmark
|
WiLD is a networking platform for women in senior positions in business and academia that is motivating and focused on science. | $68.8K / Grant / Jun 13, 2023 | |
VarmX
|
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer. | $37M / Series B / May 25, 2023 | |
|
VarmX
|
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer. | $37M / Series B / May 25, 2023 | |
| See all 70 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Lundbeckfonden Ventures invest in?
Lundbeckfonden Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 70 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Lundbeckfonden Ventures's check size?
Lundbeckfonden Ventures typically joins rounds of $10M–$50M at Series A, $20M–$95M at Series B and $16M–$53M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Lundbeckfonden Ventures participates in.
How do I contact Lundbeckfonden Ventures?
Public channels for Lundbeckfonden Ventures include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Lundbeckfonden Ventures?
The team at Lundbeckfonden Ventures includes Jette Bundgard (Associate) and Johan Kördel (Senior Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
